N.Y. Attorney General Sues Former Emergent BioSolutions CEO Robert Kramer for Insider Trading

New York Attorney General Letitia James sued former Emergent BioSolutions CEO Robert G. Kramer for insider trading, alleging he sold shares for over $10.1 million using non-public information about contamination in AstraZeneca COVID-19 vaccine production.345

Kramer learned of contamination issues as early as October 6, 2020, via a PowerPoint presentation, and implemented a trading plan on October 14, 2020, approved by Emergent on November 13, 2020; sales occurred in January-February 2021 before public disclosure.35

Emergent BioSolutions settled with the AG's office, agreeing to pay $900,000 in penalties and improve executive trading policies for approving Kramer's plan.234

The lawsuit seeks damages, disgorgement of gains, and costs from Kramer under New York's Martin Act; stock price declined after sales, and FDA halted production in April 2021.35

Kramer's lawyer called the lawsuit baseless and an overreach.5

Sources:

2. https://www.bioworld.com/articles/728020-former-emergent-ceo-faces-insider-trading-allegations

3. https://ag.ny.gov/press-release/2026/attorney-general-james-sues-former-ceo-emergent-biosolutions-insider-trading

4. https://www.biospace.com/policy/former-emergent-ceo-hit-with-insider-trading-lawsuit

5. https://abcnews.go.com/US/former-biotech-ceo-sued-covid-vaccine-alleged-insider/story?id=129255131